Sometimes in experimental biology the very factor that is part of the disease-causing mechanism can also be the factor that helps to counterbalance the disease itself.
This is the case with a new treatment for anthrax. Researchers have found that by altering an enzyme produced by Bacillus anthracis, it is possible to create a therapeutic that has the potential to prevent an infection of the zoonotic disease from occurring. So far, the developed compound has only been tested using mice (albeit with considerable success). However, the agent could help to overcome the increase in antimicrobial resistant forms of anthrax.
Sandle, T. (2022) Experimental enzyme shows promise as a prophylaxis to anthrax spores, Infectious Disease Hub, at: https://www.id-hub.com/2022/01/11/experimental-enzyme-shows-promise-prophylaxis-anthrax-spores/?utm_campaign=IDH%20-%20Q4%202021%20Tim%20Sandle%20post&utm_source=twitter&utm_medium=social&utm_term=TS
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
No comments:
Post a Comment
Pharmaceutical Microbiology Resources